Introduction
Cancer of the colon and rectum is presently the second most common cause of deaths from cancer, with over 148 300 new cases and 56 600 deaths per year in the United States. 1 Despite new insights into the molecular pathogenesis of colorectal cancer and improvements in surgery, radiotherapy, monoclonal antibody therapy and chemotherapy, the median survival of patients with metastatic disease has remained almost unchanged for the last 40 years at approximately 15 months. 2 As Heidelberger et al.
3 discovered 5-fluorouracil (5-FU) about 50 years ago, it has remained one of the most effective single-agent treatments for advanced colorectal cancer, with response rates of B11% as a single agent. 4 Strategies aimed at enhancing the therapeutic efficacy of 5-FU have involved changes in its administration schedule and also its use in combination with other antineoplastic agents or biochemical-modulating agents, like the reduced folate leucovorin (LV). 5 In recent years, several promising new agents for the treatment of colorectal cancer, among which are the novel inhibitor of the DNA enzyme topoisomerase I, irinotecan and oxaliplatin, 6 have been introduced. A combination chemotherapy regimen consisting of infusional 5-FU/ LV and oxaliplatin, known as FOLFOX, exhibits response rates of 25-40% as first-line treatment and B10% for second-line treatment. 7 In this study, we evaluated in vitro using Chou-Talalay analysis and in a subcutaneous xenograft tumor model whether the expression of measles virus fusogenic membrane glycoproteins (FMGs) H and F will enhance clinically relevant chemotherapy in permanent pancreatic cancer cell lines and short-term cultures.
In measles virus, the hemagglutinin (H) protein mediates attachment to its receptor on the target cell (CD46 or CD150) 8, 9 and thus triggers conformational changes in the virus fusion (F) glycoprotein. 10 This leads to a biologically active fusogenic form of the F protein that interacts with the host cell membrane, causing virus-cell or cell-cell fusion. 11 Both H and F proteins are necessary for fusion to occur. As intratumoral expression of fusogenic glycoproteins leads to syncytia formation of infected cells with adjacent cells, it poses an option of increasing the dispersion of viruses throughout the tumor, lateral spread of the transgene, virus release and immunogenicity of tumor cells. [12] [13] [14] [15] [16] For cancer gene therapy, fusogenic glycoproteins from HIV-1, 13 gibbon ape leukemia virus (GALV) 12, 14 and measles virus 15 have been evaluated.
As replication-competent vectors result in a far better gene transfer efficiency than their replication-defective counterparts, [17] [18] [19] [20] we trans-complemented the replication-defective FMG encoding vectors with the respective oncolytic replication-restricted adenovirus or herpes simplex virus (HSV)-1 vector (Ad.COXDMK 21 or G47D 22 ). In this setting, cells transduced/infected with the replication-defective vector encoding FMG and replication-competent oncolytic vector, the replicationdefective vector will be trans-complemented to allow vector amplification and intratumoral spread and thus improved tumor transduction. Furthermore, oncolytic adenoviruses and HSV-1 on their own can enhance the efficacy of chemotherapy. [23] [24] [25] To our knowledge, this is the first report analyzing the interaction of viral fusogenic glycoproteins and chemotherapy for the treatment of cancer alone or in combination with a trans-complementing oncolytic replication-restricted adenovirus or HSV-1-based vectors.
Results
High in vitro transduction efficiency of colorectal cancer cells with Ad.Luc and HSV.Luc As shown in Figure 1 , transduction of the established colorectal cancer cell lines with Ad.Luc and HSV.Luc resulted in a median luciferase activity of 4.6 Â 10 6 and 5.7 Â 10 6 RLU/10 3 cells, respectively, whereas incubation of the short-term cultures with these vectors produced a median luciferase activity of 1.1 Â 10 6 and 2.7 Â 10 6 RLU/ 10 3 cells, respectively. With both vectors, the transduction efficiency of the short-term colorectal cancer cells was significantly reduced by factor 4.2 and 2.1, respectively, when compared to the tested established cell lines (Student's t-test, Po0.04). Furthermore, when compared to HSV.Luc, the transduction efficiency of short-term colorectal cancer cells, but not of permanent cell lines, with Ad.Luc was significantly lower (Po0.007).
Synergism between FMG expression and chemotherapy in vitro
After demonstrating that even short-term cultures of colorectal cancer cells can be efficiently transduced with the used viral vectors, we then assessed in vitro using the median-effect principle and the combination-index (CI) method 26 whether the expression of measles virus fusogenic membrane proteins will enhance chemotherapy.
As shown in Table 1 , we determined by a chemiluminescence-based assay for each drug the dose necessary to cause a cytotoxic effect in 50% of the cells (ED 50 ). For Ad.H/F, the ratio 6:1 of particles to GTUs was used to calculate the molarity, which translates into 6.022 Â 10 23 viral particles ¼ 1 mol. 27 This provided the basis for the appropriate ratio of Ad.H/F and chemotherapeutic drugs. The ratio was kept constant when the drugs were studied in combination. The interaction of the drugs was analyzed with the software CalcuSyn. 28 The dose-effect curves and CI plots are shown in Figure 2 . In the CI plots, values above 1 indicate antagonistic drug effects, whereas those below 1 are considered synergistic. A CI of 1 suggests additive effects of both drugs. The resulting dose reduction of FMG expression and chemotherapy Adding the Ad.Luc vector to the tested chemotherapeutic agents did not result in an enhanced cytotoxicity, indicating that the effects observed with Ad.H/F are owing to the FMG expression and not owing to the viral vector backbone (data not shown).
Increased apoptosis and heat-shock protein expression following FMG expression and chemotherapy
In an attempt to elucidate the underlying mechanism of the synergistic interaction of measles virus fusogenic 
rel. tountreatedcontrol (Table 3) and survival (Table 3 and Figure 5 ). As shown in Table 3 , untreated animals had a median survival of 26 days. Administration of the replication-defective Ad.H/F in combination with FOLFOX resulted, despite the limited tumor transduction efficiency of these vectors, in a significantly improved survival when compared to single-agent treatment (41 days, Po0.002). However, there were no long-term survivors.
In order to enhance the fraction of tumor cells expressing measles virus FMG, we trans-complemented the replication-defective Ad.H/F or HSV.H/F vector with the respective replication-restricted Ad.COXDMK or G47D vector. In combination with chemotherapy, this novel triple therapy had the highest treatment efficacy (Po0.001), and was more effective than treatment with its components as single-or double-agent therapy. At the end of the observation period (day 100), animals that received the adenoviral or HSV-1-vector-based triple therapy, four and eight out of 10 animals were alive and tumor-free, respectively.
However, this improved antineoplastic efficacy was not only owing to the increased fraction of tumor cells expressing FMG. Intratumoral administration of the Ad.COXDMK or G47D vector alone resulted in an enhanced survival (44 and 58 days, respectively, Po0.001), which was further improved by co-administration of the respective FMG encoding vector (Pp0.016). This treatment regimen resulted in one long-term survivor each. Animals that received Ad.COXDMK or G47D in combination with FOLFOX had an increased survival when compared to animals treated with virus alone with a median survival of 51 and 62 days, respectively (Po0.001).
It might be noteworthy that we did not observe toxic effects owing to the FMG expression in the animals.
Discussion
In this report, we quantitatively analyzed the interactions between the expression of measles virus fusogenic membrane proteins (FMG) and chemotherapy. In vitro, we demonstrated with the median-effect principle described by Chou and Talalay, 30 in permanent colorectal cancer cells lines (DLD-1 and HT-29) but also in shortterm cultures, that the expression of FMG in combination with chemotherapy frequently causes synergistic cell killing over most of the cytotoxic dose range. As permanent cell lines often have been in continuous culture for many years and thus are likely to have genetic aberrations, it is important for the potential clinical applicability of this strategy that we confirmed our finding in short-term cultures of colorectal cancer.
Furthermore, we demonstrated in vitro that not only permanent colorectal cancer cell lines can be effectively 
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transduced with a human Ad5-or HSV-1-based gene transfer vector, but also the tested short-term cultures of colorectal cancer cells. This is important for the clinical applicability of this strategy as short-term cultures of human melanoma cells, for instance, are difficult to transduce with an Ad5-based vector in contrast to permanent melanoma cell lines. 31 However, the transduction efficiency of the short-term cultures of colorectal cancer cells when compared to the permanent cell lines (DLD-1 and HT-29) was significantly reduced by up to 4.2-and 2.1-fold, respectively.
The annexin V binding of cells expressing FMG and treated with FOLFOX was B6-fold higher when compared to cells treated with the individual compounds. Thus, one conceivable explanation for the synergistic toxicity is the proapoptotic effect of the FMGs in combination with chemotherapy. This observation might be supported by another study demonstrating that expression of viral FMGs causes syncytia formation with bioenergetic cell death. 32 However, the expression of Hsp60, which may facilitate the activation of procaspase-3, 33 which in turn participates in the acceleration of caspase activation, was not influenced by the FOLFOX treatment, alone or in combination with Ad.H/F. Furthermore, we demonstrated that the expression of measles virus FMG resulted in increased levels of Hsp70 and Hsp90a, which were further enhanced by FOLFOX. Previously, Bateman et al. 16 demonstrated that GALV fusogenic membrane protein expression resulted in increased Hsp70 levels. Furthermore, it has been reported that the induction of Hsp70 expression enhances tumor immunogenicity, 34 and can protect cells against death by directly interfering with mitochondrial apoptosis pathways. 33 However, Hsp70 as well as Hsp90a also sensitizes cells to certain apoptotic stimuli like tumor necrosis factor-a. 33, 35 In our experiments, infection with adenovirus alone resulted in a somewhat upregulation of Hsp90a expression, as reported previously, 36 but not of Hsp70. Owing to poor intratumoral dispersion of currently available replication-defective viral vectors, even after intratumoral injection, gene transfer rates are very low and usually confined to the close proximity of the injection site. 37, 38 However, despite these limitations, we were able to demonstrate in the subcutaneous colorectal xenograft model that the intratumoral injection of a replication-defective vector encoding FMG in combination with FOLFOX chemotherapy regimen resulted with both vector systems in a significantly higher treatment efficacy than treatment with the individual compounds.
Previously, it has been demonstrated by several groups in preclinical tumor models that the fraction of genetically modified tumor cells will be greatly enhanced when a replication-defective viral vector encoding a therapeutic gene is co-administered with a virus or viral vector that trans-complement each other for missing gene products pivotal for vector replication and thus each tumor cell that is successfully co-transduced would itself become a virus-producing cell, thus initiating further transduction events in situ. [17] [18] [19] [20] 39 In contrast to HSV-1-based vectors, this trans-complementation strategy is important for adenoviral vectors, as most of the replication-competent vectors cannot carry a therapeutic gene owing to size constraints. In our Ad.COXDMK vector, the B6.4 kb FMG expression cassette would have exceeded viral packaging capacity. 40 Thus, we trans-complemented the Ad.H/F and HSV.H/F vector with the replication-restricted adenovirus Ad.COXDMK or HSV-1 G47D vector.
Our new triple therapy consisting of measles virus FMG expression, chemotherapy and trans-complementing oncolytic replication-restricted vectors strongly enhanced the antineoplastic treatment efficacy. We observed similar data with two vector systems. At the end of the observation period (day 100), in the treatment groups that received oncolytic vectors in combination with the respective vector encoding FMG without chemotherapy one animal each was alive. When chemotherapy was added to this double-agent adenovirus or HSV-1-based treatment regimen, four and eight animals out of 10 were alive and tumor-free at the end of the observation period.
Responsible for this improved treatment efficacy are several factors that worked in concert: first, owing to the trans-complementation strategy, a greater percentage of the tumor cells expressed FMG. Second, oncolytic adenoviral or HSV-1-based vectors can enhance the efficacy of chemotherapeutic agents by themselves. 23, 24 However, this effect is negatively affected by the virostatic effect of the chemotherapeutics. 41, 42 As we observed in our tumor model a slightly enhanced antineoplastic effect when just combining the oncolytic vectors with FOLFOX, in the triple therapy the transcomplementation approach improved chemotherapy to some extent independently of the FMG expression. Third, without using chemotherapy, several groups reported previously that the intratumoral expression of FMG enhances the efficacy of virotherapy. 12, 14, 43 We were able to confirm these findings in our tumor model not only in the context of oncolytic adenoviral but also HSV-1-based vectors.
The oncolytic efficacy of G47D alone or in combination with HSV.H/F and FOLFOX was significantly greater than the corresponding adenovirus-based treatment. This is remarkable as at any given time point only a small fraction of tumor cells are in the S-phase that support productive replication of G47D. In contrast, productive infection of cells with Ad.COXDMK is cell type dependent, but independent of the cell cycle status.
In summary, intratumoral expression of measles virus FMGs can enhance the efficacy of chemotherapy. Treatment outcome can be further improved by the combination with trans-complementing oncolytic viruses. The reasons for this are multi-causal. As it has been previously reported that fusogenic membrane proteins can enhance the immunogenicity of tumor cells, 16 this approach might be even more effective in an immunocompetent host.
Materials and methods
Cells and cell culture
The permanent human cell lines DLD-1, 44 HT-29, 45 293, A549 and HeLa were obtained from the ATCC (Manassas, VA, USA). The Vero 2-2 cells were kindly provided by Dr Rozanne Sandri-Goldin (University of California, Irvine, CA, USA) via Dr Cornell Fraefel (University of Zurich, Switzerland). 46 HaCaT cells were a gift from Dr N Fusenig (DKFZ, Heidelberg, Germany).
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We established short-term cultures of colorectal cancer cells, designated PCC #1 and PCC #2, from patients who underwent surgery for treatment of histologically confirmed colorectal cancer, as described previously. 21 Ethical clearance was obtained from the local Ethics Committee (Registration No. 2487).
Generation of stable luciferase-expressing cell lines
The polyclonal constitutively firefly luciferase-expressing cell lines DLD-1-Luc3 and HT-29-Luc3 were generated by transduction with an murine leukemia virus-based retrovirus encoding luciferase (GC Luc3 EN 47 ) and subsequent neomycin selection.
Viruses
The replication-defective adenoviral vector Ad.Luc encoding firefly luciferase (pGL3basic, Promega, Madison, WI, USA) driven by the hCMV-IE promoter was generated with the Ad-Easy system. 48 In the tumorrestricted replication-competent human Ad5 virus Ad. COXDMK, 21 the adenoviral E1 and E4 gene products, which are essential for viral replication, are transcriptionally targeted by the cyclooxygenase-2 (COX-2 À327/ +59) 49 and midkine (MK À1009/+25) 50 promoter. Using two different promoters to drive viral E1 and E4, replication selectivity was enhanced by B85% when compared to the respective solitary E1-controlled vector. 21 The replication-defective adenoviral vector Ad.H/F encodes the measles virus FMG under the transcriptional control of the tumor-specific human telomerase reverse transcriptase promoter (hTERT À548/+5). 51 For this, the CMV-IE promoter of the measles virus H and F bicistronic expression plasmid pGC-H/IRES/F 29 (kindly provided by Professor Roberto Cattaneo, Rochester, MN, USA) was replaced with the hTERT promoter from the plasmid pBTdel-548 51 (kindly provided by Dr Izumi Horikawa, NCI, NIH, Bethesda, MD, USA) and inserted into the multiple cloning site of pAd.Track, 48 creating pAd.Track hTERT H/F. Infectious viral vector was generated with the Ad.Easy-1 system, as described previously. 48 The reference strain VR-5 (ATCC, Manassas, VA, USA) was used as wild-type adenovirus type 5. The vectors Ad.Luc and Ad.H/F were amplified in 293 cells: the Ad.COXDMK vector and Ad5 in HeLa cells. Adenoviruses were purified by cesium chloride gradient centrifugation, as described previously. 52 The replication-restricted oncolytic HSV-1 G47D
22
(kindly provided by Dr Samuel Rabkin, MGH, Charlestown, MA, USA) is derived from wild-type HSV-1 strain F, which has deletions in both copies of the g34.5 gene, the major determinant of HSV neurovirulence, 53 inactivated infected cell protein (ICP)6 and lacks the ICP47 gene product. The latter abrogates the downregulation of major histocompatibility complex class I. 54, 55 ICP6 is the large subunit of ribonucleotide reductase, a key enzyme for nucleotide metabolism and viral DNA synthesis in non-dividing cells but not in dividing cells. 56 For the generation of helper-virus-free HSV.Luc amplicon vector, the coding sequence for firefly luciferase (pGL3basic, Promega) was cloned into the HSV amplicon plasmid vector pHSVPrPUC (kindly provided by Dr Cornel Fraefel) under the transcriptional control of the hCMV-IE promoter, resulting in pHSVPrPUC CMV Luc. For HSV.Luc amplicon vector production, Vero 2-2 cells were co-transfected with the HSV-1-BAC clone fHSVDpacD27kn 57 (kindly provided by Dr Yoshinaga Saeki, MGH, Charlestown, MA, USA) and pHSVPrPUC CMV Luc.
To generate an HSV-1 amplicon vector encoding measles virus FMG under the transcriptional control of the hTERT promoter, the 8.1 kb SgrAI-XhoI fragment of pAd.Track hTERT H/F, containing the green fluorescent protein (GFP) and measles virus H and F expression cassettes. was inserted into the polylinker of the plasmid pHSVPrPUC linker, generating pHSVPrPUC hTERT H/F.
To package HSV.H/F amplicon, Vero 2-2 cells were transfected with pHSVPrPUC hTERT H/F. Approximately 20 h after transfection, the G47D vector was added as helper virus at an MOI of 0.2. After 1 h, additional media containing 5% fetal calf serum was added and amplicon virus stocks harvested 2 days later when complete cytopathic effect was observed. The amplicon to helper virus ratio was determined by titering each component separately. The vectors Ad.H/F and HSV.H/F were generated and produced in the presence of the synthetic fusion-inhibitory peptide Z-D-Phe-PheGly-OH (10 mM; Bachem AG, Bubendorf, Switzerland). 58 All HSV-based vectors were purified by ultracentrifugation through a 40% sucrose cushion.
The bioactivity of the Ad.Luc and HSV.Luc vectors were determined on 293 cells by bioluminescence and expressed as GTUs/ml. 27 The titers (GTU/ml) of the Ad.H/F and HSV.H/F vectors, both encoding GFP by a second transcription unit, were determined in the presence of the synthetic fusion-inhibitory peptide by flow cytometry 59 on DLD-1, HT-29, PCC #1, A549 and 293 cells. The activity of the Ad.COXDMK and G47D vectors were determined on the same panel of cells by TCID 50 . 27 Viral transduction efficiency DLD-1, HT-29, PCC #1, PCC #2 and 293 cells were seeded at a concentration of 1 Â 10 3 cells/well in 100 ml into 96-well flat-bottom culture plates. After 12 h, cell monolayers were transduced with a defined amount (3 Â 10 2 GTU) of Ad.Luc or HSV.Luc, resulting in 30% of the maximum obtainable luciferase activity in 293 cells 24 h post-infection. Twenty-four hours post-infection, cell monolayers were washed with phosphate-buffered saline (PBS) and luciferase assay was carried out as described above.
Analysis of combined drug effects
Cells were treated with serial dilutions of each drug individually or with a fixed ratio of both drugs simultaneously at doses that corresponded to i, g, l, h, 1 and 1i times the respective ED 50 . When the two drugs were administered at a fixed ratio, the dose of the combination required to produce fractional survival (f) could be separated into the components (D) 1 and (D) 2 26, 60 When the concentration-effect relationship follows the principle of mass action, the median-effect plot should be linear. Linear correlation coefficients (r) were generated for each curve to determine the applicability of the data to this method of analysis. In all experiments, r was 40.9.
Thirty-six hours after treatment, cytotoxicity of the DLD-1-Luc3, HT-29-Luc3 cell lines were determined by bioluminescence. For the short-term cultures of colorectal cancer, not genetically engineered to express luciferase, cytotoxicity was analyzed using the CellTiter-Glot Luminescent Cell Viability Assay (Promega), as recommended by the manufacturer.
The following chemotherapeutic drugs were evaluated: 5-FU (Hexal, Holzkirchen, Germany) with LV (Hexal), irinotecan (CPT-11; Pfizer Pharma GmbH, Karlsruhe, Germany) and oxaliplatin (Sanofi-Aventis GmbH, Frankfurt, Germany).
Analysis of apoptosis and Hsp expression
Fourteen hours after treatment, annexin V binding and caspase-3/7 activity of DLD-1 or HT-29 cells was analyzed with the Annexin V-FITC Apoptosis Detection Kit I (BD, Mansfield, MA, USA) or Caspase-Glot 3/7 assay (Promega, Madison, WI, USA), respectively, according to the manufacturer's instructions.
Hsp60 expression was analyzed by Western blotting employing two rounds of precipitation with agaroseconjugated (AC) goat IgG and anti-Hsp60 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) at 41C. After blotting, for Hsp60 detection, the antibody SPA806 (Stressgen, Victoria, BC, Canada) was used. Hsp70 and 90a expression was analyzed by enzyme-linked immunosorbent assay (StressExpress ELISA Kit, Stressgen) as recommended by the manufacturer.
Animal studies
This study was approved by the local Animal Care and Use Committee. Six-to eight-week-old female athymic nude (Balb/c nu/nu) mice were obtained from Janvier (Le Genest-St-Isle, France). To establish a subcutaneous colorectal xenograft model, nude mice received subcutaneously 1 Â 10 7 HT-29 cells in 100 ml into the hind flanks. When the tumors reached a volume of B200 mm 3 , animals were randomly assigned to treatment groups (n ¼ 10).
Animals treated with the oncolytic viruses or the measles virus FMG encoding vectors alone or in combination with FOLFOX received intratumoral in 100 ml PBS on day 0, day 1 and day 2, 2 Â 10 8 TCID 50 or GTU determined on HT-29, respectively. Animals treated with the oncolytic viruses in combination with Ad.H/F or HSV.H/F received per treatment cycle 1 Â 10 8 TCID 50 plus 1 Â 10 8 GTU (determined on HT-29) alone or in combination with FOLFOX. FOLFOX (5-FU/LV+Ox; 40/ 16/1 mg/kg/day) was given in 3 ml 0.9% NaCl solution intraperitoneally once a day for 5 consecutive days starting on day 4.
At least once a week, minimum and maximum perpendicular tumor axes were measured using vernier calipers, and tumor volume was calculated using the simplified formula of a rotational ellipse (l Â w 2 Â 0.5).
The skin thickness of 0.4 mm was subtracted from the measurements. Animals were maintained under specific pathogen-free conditions and were killed with CO 2 if their tumors exceeded 10% body weight or if the mice appeared to be in distress.
Statistical methods and median-effect analysis
The statistical software package SPSS 13 (SPSS Inc., Chicago, IL, USA) was used for data analysis with indicated tests. Analysis of combined effects of multiple drugs, described by Chou and Talalay, 30 was performed with the software CalcuSyn 2.0 (Biosoft, Cambridge, UK).
